Edition:
United States

Madrigal Pharmaceuticals Inc (MDGL.OQ)

MDGL.OQ on NASDAQ Stock Exchange Capital Market

118.92USD
20 Apr 2018
Change (% chg)

$-0.08 (-0.07%)
Prev Close
$119.00
Open
$118.64
Day's High
$121.00
Day's Low
$116.85
Volume
53,103
Avg. Vol
85,456
52-wk High
$154.35
52-wk Low
$13.11

Chart for

About

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product,... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $1,691.95
Shares Outstanding(Mil.): 14.23
Dividend: --
Yield (%): --

Financials

  MDGL.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -2.54 -- --
ROI: -28.49 -0.74 13.19
ROE: -28.49 -2.80 15.00

BRIEF-Madrigal Pharmaceuticals Qtrly ‍Loss Per Share $0.67​

* MADRIGAL PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS, REVIEWS KEY CORPORATE ACHIEVEMENTS AND PROVIDES CLINICAL UPDATE ON MGL-3196

Mar 13 2018

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Heterozygous Familial Hypercholesterolemia

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HEFH)

Feb 08 2018

BRIEF-Madrigal Pharmaceuticals Prices Public Offering Of Common Stock

* MADRIGAL PHARMACEUTICALS PRICES PUBLIC OFFERING OF COMMON STOCK

Dec 18 2017

BRIEF-Madrigal Pharma Announces Proposed Public Offering Of Common Stock

* MADRIGAL PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Dec 18 2017

BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial

* MADRIGAL'S MGL-3196 ACHIEVES PRIMARY ENDPOINT IN PATIENTS WITH BIOPSY-PROVEN NON-ALCOHOLIC STEATOHEPATITIS (NASH) IN PHASE 2 CLINICAL TRIAL

Dec 06 2017

BRIEF-Madrigal Pharmaceuticals reports Q3 loss per share of $0.68

* Madrigal Pharmaceuticals reports 2017 third quarter financial results

Nov 09 2017

Earnings vs. Estimates